BioNTech SE (FRA:22UA)
Germany · Delayed Price · Currency is EUR 85.00
-2.60 (-2.97%)
Jan 8, 2026, 9:12 PM CET
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
€465,520
Profits / Employee
€84,406
Market Cap
21.54B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Bayer Aktiengesellschaft | 91,864 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 59,020 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,784 |
BioNTech SE News
- 18 days ago - Trader-Interview mit Tipp-Checker Flo: PayPal, Tesla, BioNTech, 21shares HODL & 21shares ALTS • news - Onvista
- 24 days ago - BioNTech SE: BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - Finanz Nachrichten
- 24 days ago - BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - GlobeNewsWire
- 26 days ago - Noteworthy ETF Inflows: FNDF, APTV, BNTX, NXPI - Nasdaq
- 4 weeks ago - BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
- 4 weeks ago - BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
- 4 weeks ago - BioNTech, Bristol-Myers Squibb Announce Interim Results From Pumitamig Study - Nasdaq
- 4 weeks ago - BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - Finanz Nachrichten